Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

407

HTML

4417

Figures (1-2)

121

Tables (1-11)

144

Sum=5089

Aug 15, 2002 (publication date) through Apr 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Aug 15, 2002; 8(4): 679-685
Published online Aug 15, 2002. doi: 10.3748/wjg.v8.i4.679

Table 5 Abnormal rates of serum fibrotic markers before and after treatment (abnormal rate (%) = number of abnormal cases/total cases)

^aP < 0.05, vs before treatment.

Citation: Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002; 8(4): 679-685
URL: https://www.wjgnet.com/1007-9327/full/v8/i4/679.htm
DOI: https://dx.doi.org/10.3748/wjg.v8.i4.679